Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency

详细信息    查看全文

• 作者：Vaishali B. Popat ; Vien H. V ; erhoof ; Karim A. Calis ; James F. Troendle ; Lawrence M. Nelson
• 关键词：Transdermal estradiol therapy ; premature ovarian failure ; premature menopause ; primary ovarian insufficiency ; primary hypogonadism ; hypergonadotropic hypogonadism ; LH ; FSH ; hormone therapy
• 刊名：Fertility and Sterility
• 出版年：2008
• 出版时间：February 2008
• 年：2008
• 卷：89
• 期：2
• 页码：429-433
• 全文大小：131 K

文摘

Objective

To determine the proportion of women with primary ovarian insufficiency who achieve normal serum LH levels on transdermal E₂ therapy.

Design

Prospective.

Setting

Clinical research center at a national US health research facility.

Patient(s)

Women with spontaneous primary ovarian insufficiency (n = 137) and 70 regularly menstruating control women (n = 70).

Intervention(s)

Blood sampled from controls in the midfollicular phase and from patients while they were off E₂ for 2 weeks, then again 3 months later during the E₂-only phase of hormone therapy (E₂ patch [100 μg/d] and oral medroxyprogesterone acetate [10 mg for 12 d/mo]).

Main Outcome Measure(s)

Serum LH.

Result(s)

While on transdermal E₂ therapy, significantly more women (51.1 % , 70/137; 95 % confidence interval, 42 % , 60 % ) had serum LH levels in the normal range (5/137, 3.9 % at baseline). Mean (SD) serum E₂ level significantly increased on therapy to 95.4 (84.9) pg/mL.

Conclusion(s)

A regimen of 100 μg/d of transdermal E₂ therapy achieves normal serum LH levels in approximately one half of women with spontaneous primary ovarian insufficiency. Theoretically, by avoiding inappropriate luteinization, physiologic E₂ therapy may improve follicle function in these women. Controlled studies to assess the effect of transdermal E₂ therapy on follicle function in these women are warranted.